Analgesic Solutions Report issue

For profit Phase 2 Phase 4
Founded: Wayland MA United States (2006)
Status: Acquired by WIRB-Copernicus Group (2019)

Organization Overview

First Clinical Trial
2011
NCT01264237
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 4 Trials (3)

etoricoxib (Gencox) (1 trial)

milnacipran (savella) (1 trial)

pregabalin (lyrica) (1 trial)

Drugs in Phase 2 Trials (1)

prednisone (meticorten) (1 trial)

Drugs in Other Trials (1)

naproxen (naprosyn) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Neuropathies (Phase 4)

Giant Cell Arteritis (Phase 2)

Neuralgia (Phase 4)

Neuralgia, Postherpetic (Phase 4)

Osteoarthritis (Phase 4)

Pain (Phase 4)

Polymyalgia Rheumatica (Phase 2)

Polyneuropathies (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 5